Unlike compounded GLP-1, these are the FDA-approved branded products. Manufacturer direct-to-consumer self-pay prices dropped sharply in 2025–2026, which narrows the old price gap with compounded. Verified on the manufacturers’ own pages on 2026-06-25.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Product | Channel | Self-pay price | Notes | Provenance |
|---|---|---|---|---|
| Zepbound (tirzepatide) | LillyDirect vials | $299 (2.5mg) · $399 (5mg) · $449–$499 (7.5–15mg) | $449 needs refill within 45 days; else $499–$699 | primary (Lilly) |
| Wegovy (semaglutide) inj. | NovoCare | $349 std · $199 intro (first 2 mo, low doses) | HD 7.2mg ~$399; lowered from $499 | primary (Novo) |
| Wegovy (semaglutide) pill | NovoCare | $149–$299 | Varies by dose | primary (Novo) |
| Ozempic (semaglutide) | NovoCare | $349 std · $199 intro · $499 (2mg) | Diabetes-indicated | primary (Novo) |
With commercial insurance and a savings card, eligible patients may pay as little as $25/mo (government beneficiaries excluded). These FDA-approved products are reviewed for safety, effectiveness, and quality — unlike compounded GLP-1. Prices and offers change; verify on the manufacturer’s site.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.